June 9, 2025 02:11 PM EDTUpdated June 10, 08:39 AM
R&D
Pharma
FDA+

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

Max Bayer

Pharma Reporter

The FDA ap­proved Mer­ck’s RSV an­ti­body for ba­bies, tee­ing up a ri­val­ry with Sanofi and As­traZeneca’s Bey­for­tus.

The de­ci­sion adds a new en­trant to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times